Pfizer snaps up gene therapy group Bamboo for $645m
Pfizer has snapped up the remaining stake in privately-held, US gene therapy group Bamboo Therapeutics in a deal that could be worth as much $645 million.
Read More
Tag: Bamboo
- Oxford BioTherapeutics signs collaboration with Bristol Myers Squibb
- Kainova expands DT 7012 trial into Europe
- Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease
- CatalYm begins phase 2b trial of visugromab in second-line liver cancer treatment
- FDA approves new high dose Spinraza regimen for SMA
